Effect of compound 15 and sorafenib on HT-29.cell cycle progression.
| Sample | Cell cycle distribution (%) | ||
|---|---|---|---|
| % G0-G1 | % S | % G2/M | |
| Compound 15/HT-29 | 58.26 ± 1.74 | 33.04 ± 2.22a | 8.70 ± 0.6a |
| Sorafenib/HT-29 | 51.95 ± 1.05a,b | 41.06 ± 1.49a,b | 6.99 ± 1.01a,b |
| Control HT-29 | 61.44 ± 1.56 | 25.82 ± 0.62 | 12.74 ± 1.7 |
Significant P value from control HT-29.
Significant P value from compound 15/HT-29, significant P value <0.05 & by using One-way ANOVA followed by Tukey's post hoc multiple comparison tests.